What is Proviron?
Proviron (Mesterolone) is an oral DHT derivative with a special role: it is not a mass-building steroid but a "support compound". It is not 17a-alkylated and therefore barely liver-loading. Clinically it was used for libido and fertility topics.
This information is for research and educational purposes only. No medical advice.
Comparison
Androgens in the lexicon
Mesterolone and related androgens, as described in the TPD lexicon. Tap a card to open its entry.
In the same lab study methenolone bound the androgen receptor more strongly than testosterone and mesterolone. Mesterolone instead stood out for its strong binding to SHBG. 2
How it works
Proviron binds strongly to SHBG (sex hormone binding globulin) and lowers it - raising the fraction of free, active testosterone in the blood. It also has a weak anti-estrogenic effect and binds the androgen receptor itself. That makes it a popular add-on compound that makes other steroids "freer" and more effective and supports well-being/libido.
Where it acts
Where mesterolone acted in studies
Tap a point or a card. Colour = target, grey = observed in studies.
- Blood (SHBG)
Binds SHBG about 4 times more strongly than DHT2
SHBG - Muscle and prostate
Binds the androgen receptor more weakly than testosterone (rats)2
AR - Testes
Sperm more motile, but also with placebo, no more pregnancies3
Observed in trials - Libido and mood
In hypogonadism weaker than testosterone undecanoate5
Observed in trials - Liver
One case report of liver injury7
Observed in trials
Known targets2
Compound PubChem CID 15020: two described targets, type of action on each card.
- Gene
- SHBG
- UniProt
- P04278
- ChEMBL
- CHEMBL3305
- Action
- Binds strongly, about 4 times more than DHT
- Gene
- AR
- UniProt
- P10275
- ChEMBL
- CHEMBL1871
- Action
- Binds, more weakly than testosterone
Use and dosing
Dosing
Dosing, titration and syringe
Loading the dosing information …
- Getting started and stepping up, drawn as a staircase
- Units on the U-100 syringe for every step
- How long one vial lasts
What the research shows
The AAS pharmacology (Kicman 2008) describes the SHBG binding and androgenic action of mesterolone. As a non-17a-alkylated DHT derivative the liver risk is low.
Study results
What the trials measured
Interactive: switch tabs, tap points, show or hide arms. Arms are named relative to each other, no dosing advice.
How strongly mesterolone binds SHBG2
Relative binding, DHT = 1
According to the abstract about 4 times stronger than DHT, order of SHBG binding: mesterolone ahead of DHT ahead of testosterone. At the androgen receptor in rat muscle and prostate mesterolone bound more weakly than testosterone, methenolone and nandrolone.
Pregnancies in 12 months3
52 men with reduced sperm quality, double-blind, share in percent
Similar according to the authors, no benefit from mesterolone. Sperm motility and shape improved, but also with placebo. A second study of 368 men over 9 months also found no difference compared with vitamin C.
Research status
Where the research stands
Mesterolone is an old drug. The human studies date from before the registry, which lists not a single one. As of 26 Oct 2026. 9
- Preclinical Binding to SHBG and androgen receptor
- Phase 1 no registered trial
- Phase 2 no registered trial
- Phase 3 no registered trial
- Approval according to ChEMBL, not in the USA
The approval predates today's trial registries, so the register shows no current trial for this form. 9
Side effects
- Androgenic (DHT derivative) - hair loss in predisposed individuals, acne.
- Very low liver load (not 17a-alkylated).
- HPTA suppression milder than with strongly anabolic steroids, but present.
- Barely any estrogen side effects.
Storage
Store dry and cool, protected from light. Out of reach of children.